Choosing between stem cell therapy and drugs in myelofibrosis.

Choosing between stem cell therapy and drugs in myelofibrosis.

Item
http://www.wikidata.org/entity/Q34734491
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.Outcome of transplantation for myelofibrosis.The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.How to manage the transplant question in myelofibrosis.Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.Safety of conditioning agents for allogeneic haematopoietic transplantation.Experimental therapeutics for patients with myeloproliferative neoplasias.Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.New JAK2 inhibitors for myeloproliferative neoplasms.Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study.Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation.(18)F-FDG PET/CT for Detection of Metachronous Hodgkin's Disease in Patients with Myelofibrosis.The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
P2860

Choosing between stem cell therapy and drugs in myelofibrosis.

Item
http://www.wikidata.org/entity/Q34734491
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Choosing between stem cell therapy and drugs in myelofibrosis.
@ast
Choosing between stem cell therapy and drugs in myelofibrosis.
@en
Choosing between stem cell therapy and drugs in myelofibrosis.
@nl
type
label
Choosing between stem cell therapy and drugs in myelofibrosis.
@ast
Choosing between stem cell therapy and drugs in myelofibrosis.
@en
Choosing between stem cell therapy and drugs in myelofibrosis.
@nl
prefLabel
Choosing between stem cell therapy and drugs in myelofibrosis.
@ast
Choosing between stem cell therapy and drugs in myelofibrosis.
@en
Choosing between stem cell therapy and drugs in myelofibrosis.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P356
P1433
P1476
Choosing between stem cell therapy and drugs in myelofibrosis.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698